AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Decline in Short Interest

AlloVir, Inc. (NASDAQ:ALVR) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 3,950,000 shares, a drop of 19.2% from the October 15th total of 4,890,000 shares. Based on an average daily trading volume, of 256,400 shares, the short-interest ratio is presently 15.4 days.

AlloVir Price Performance

Shares of NASDAQ:ALVR traded up $0.03 on Friday, reaching $0.58. The company had a trading volume of 386,619 shares, compared to its average volume of 619,426. The stock has a 50-day moving average price of $0.79 and a 200 day moving average price of $0.77. AlloVir has a twelve month low of $0.53 and a twelve month high of $2.49.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10.

Hedge Funds Weigh In On AlloVir

Institutional investors and hedge funds have recently bought and sold shares of the business. Cubist Systematic Strategies LLC raised its holdings in shares of AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after buying an additional 30,072 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of AlloVir in the 2nd quarter valued at $55,000. Price T Rowe Associates Inc. MD grew its stake in shares of AlloVir by 127.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after purchasing an additional 54,900 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in AlloVir by 694.6% in the first quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,387,666 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.